OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - GENMAB | Real-time Boerse Frankfurt Warrants 08:53:32 26/06/2024 BST | ||
| 8.19 EUR | +0.24% |
|
| Current month | +28.86% | ||
| 1 month | +21.04% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 26/06/24 | 8.19 | +0.24% |
| 25/06/24 | 8.17 | +0.74% |
| 24/06/24 | 8.11 | -0.73% |
| 21/06/24 | 8.17 | -1.57% |
| 20/06/24 | 8.3 | -6.74% |
Real-time Boerse Frankfurt Warrants
Last update June 26, 2024 at 08:53 am
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Société Générale
|
| WKN | SW884Y |
| ISIN | DE000SW884Y0 |
| Date issued | 19/04/2024 |
| Strike | 2,424 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.86 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 8.95 € |
|---|---|
| Lowest since issue | 4.72 € |
| Spread | 0.03 € |
| Spread % | 0.36% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,799
DKK
Average target price
2,464
DKK
Spread / Average Target
+36.96%
- Stock Market
- Certificates
- Certificat
